Regenxbio reported that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, clearing the key milestone required to move toward an FDA submission. The company says the therapy produced sufficiently high levels of the miniaturized muscle protein target, supporting plans for regulatory filing with a goal of possible approval in 2027. The result arrives after heightened scrutiny across the DMD gene-therapy landscape, including prior safety concerns tied to competitor products. Regenxbio positioned its data as meeting the requirements for accelerated approval, framing the dataset as a step toward a potentially more favorable risk-benefit profile.